Acute myeloid leukemia is often treated using RA-based ... They began producing well-known markers of maturation such as CD38 and CD11b, generated reactive oxygen species (ROS), and expressed ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...

However, since CD38 is strongly induced on NK cell expansion ... CLEC12A is strongly expressed by blasts in the majority of acute myeloid leukemia (AML) patients. While expressed on the leukemic ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...

This study reveals that the expression of the Src-family kinase (SFK), FGR, alone can induce cell differentiation similar to RA."BUFFALO, NY – March ...